Pakistani Company Inks Deal to Manufacture COVID-19 Vaccine
Joe Raedle-Getty Images North America AFP
Searle’s agreement with Livzon Mapharm is linked to a vaccine that is currently in Phase II clinical trials
Pakistani pharmaceutical company Searle has inked a deal with China’s Livzon Mapharm allowing it to license, manufacture, and supply a new COVID-19 vaccine in the country, according to information provided by the company to the Pakistan Stock Exchange.
“Searle Company has concluded an exclusive licensing and supply agreement with Livzon Mapharm Inc. for the Recombinant Novel Coronavirus Vaccine (V-01). The licensing agreement also covers the manufacturing transition of (V-01) in Pakistan,” reads the letter submitted by the company. It said that the vaccines was in the final phases of its clinical trial, adding that early results were promising.
A local pharmaceutical company has signed a deal with a Chinese giant that allowed it to supply and produce an upcoming Covid-19 vaccine in Pakistan. Reuters/File
KARACHI: A local pharmaceutical company has signed a deal with a Chinese giant that allowed it to supply and produce an upcoming Covid-19 vaccine in Pakistan, an official announcement said on Thursday.
This has emerged in a letter written by M/s Searle Company Limited to the Pakistan Stock Exchange, saying it had concluded an agreement with China’s Livzon Mapharm Inc. for manufacturing novel coronavirus vaccine (V-01) in Pakistan.
“Searle Company has concluded an exclusive licensing and supply agreement with Livzon Mapharm Inc. for the Recombinant Novel Coronavirus Vaccine (V-01). The licensing agreement also covers the manufacturing transition of (V-01) in Pakistan,” the company said.
SEARLE Company Limited, a Karachi-based pharmaceutical firm, has signed an exclusive licensing and supply agreement with Livzon Pharmaceutical Group, a